Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment

Phase 1

Withdrawn

• Conditions: MS Patient With Relpasing Remitting Attacks
• Interventions: Drug: Dexamethasone soduim phosphate

• Registration Number: NCT00674141
• Lead Sponsor: Hadassah Medical Organization

Brief Summary

The study aims to assess the safety and efficacy of nasale administration of Dexamethasone in relapsing MS patients

Detailed Description

Not available

Study Timeline

• Status Verified: 2008-05
• Study First Submitted: 2008-05-06
• Study First Submitted QC: 2008-05-06
• Study First Posted: 2008-05-07
• Study Start: 2008-07
• Primary Completion: 2008-12
• Study Completion: 2009-01
• Last Update Submitted: 2010-06-02
• Last Update Posted: 2010-06-03

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• MS patients with esatblished relapsing remitting attacks
• increase in EDSS of at least 1 point for a least one day

Exclusion Criteria

• children under 18
• pregnant patients
• patients with diabetes
• known allergy to steroids
• patients who received steroids within 3 months prior to the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	Dexamethasone soduim phosphate	only one experimental treated group

Primary Outcome Measures

Name	Time	Method
reduction in the EDSS functional system score	four months

Trial Locations

Locations (1)

Hadassah Medical Organization; 🇮🇱 Jerusalem, Israel